1. Home
  2. HRMY vs UNIT Comparison

HRMY vs UNIT Comparison

Compare HRMY & UNIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$37.06

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

UNIT

Uniti Group Inc.

HOLD

Current Price

$8.07

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
UNIT
Founded
2017
2015
Country
United States
United States
Employees
N/A
758
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.9B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
HRMY
UNIT
Price
$37.06
$8.07
Analyst Decision
Strong Buy
Buy
Analyst Count
8
4
Target Price
$49.75
$6.58
AVG Volume (30 Days)
612.6K
2.4M
Earning Date
02-24-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
50.44
1036.05
EPS
3.17
8.00
Revenue
$825,944,000.00
$1,610,627,000.00
Revenue This Year
$23.34
$97.87
Revenue Next Year
$16.28
$59.55
P/E Ratio
$11.49
$0.98
Revenue Growth
21.13
38.94
52 Week Low
$25.52
$5.30
52 Week High
$40.87
$10.23

Technical Indicators

Market Signals
Indicator
HRMY
UNIT
Relative Strength Index (RSI) 48.18 55.20
Support Level $36.27 $7.74
Resistance Level $38.04 $8.22
Average True Range (ATR) 1.18 0.33
MACD -0.03 0.00
Stochastic Oscillator 50.14 46.43

Price Performance

Historical Comparison
HRMY
UNIT

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About UNIT Uniti Group Inc.

Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 217,000 route-mile fiber network that primarily serves enterprise customers. This fiber business generates about 20% of consolidated revenue. Uniti also owns phone networks that reach about 4.5 million households, mostly in less-populated markets in the Southeast. Uniti is rapidly upgrading this network to offer fiber-based broadband services. Its fiber network reaches about 1.8 million locations in its service territory. Residential telecom services account for about a third of total revenue. Small business and wholesale services provided over the legacy phone network account for about 20% of revenue.

Share on Social Networks: